42564-51-2

Basic information

• Product Name: 4-FLUORO-3-NITROBENZALDEHYDE
• Synonyms: 3-NITRO-4-FLUOROBENZALDEHYDE;4-FLUORO-3-NITROBENZALDEHYDE;4-Fluoro-3-nitrobenzaldehyde,97%;2-Fluoro-5-formylnitrobenzene;4-Fluoro-3-nitrobenzaldehyde 97%;4-Fluoro-3-nitrobenzaldehyde≥ 98% (GC)
• CAS NO: 42564-51-2
• Molecular Formula: C₇H₄FNO₃
• Molecular Weight: 169.11
• EINECS: 1592732-453-0
• Product Categories: Aromatic Aldehydes & Derivatives (substituted);Aldehydes;C7;Carbonyl Compounds;Fluorine series;Halogenated Heterocycles ,Imidazoles ,Imidazolines/Imidazolidines
• Mol File: 42564-51-2.mol
• Article Data: 33

Chemical Properties

• Melting Point: 45-47 °C(lit.)
• Boiling Point: 285.996 °C at 760 mmHg
• Flash Point: >230 °F
• Appearance: White to tan/Crystalline Powder
• Density: 1.444 g/cm³
• Vapor Pressure: 0.003mmHg at 25°C
• Refractive Index: 1.59
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Sensitive: Air Sensitive
• CAS DataBase Reference: 4-FLUORO-3-NITROBENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-FLUORO-3-NITROBENZALDEHYDE(42564-51-2)
• EPA Substance Registry System: 4-FLUORO-3-NITROBENZALDEHYDE(42564-51-2)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38-22
• Safety Statements: 26-36/37/39-22
• WGK Germany: 3
• Hazardous Substances Data: 42564-51-2(Hazardous Substances Data)

Usage

Chemical Properties

White to tan crystalline powder

InChI:InChI=1/C7H4FNO3/c8-6-2-1-5(4-10)3-7(6)9(11)12/h1-4H

Upstream product

• 459-57-4 4-fluorobenzaldehyde 
• 20274-69-5 (4-fluoro-3-nitrophenyl)methanol 
• 453-71-4 3-nitro-4-fluorobenzoic acid 
• 16588-34-4 4-chloro-3-nitro-benzaldehyde 
• 20968-47-2 p-(2,2-Dichlorocyclopropyl)fluorobenzene 

Downstream Products

• 3011-34-5 4-hydroxy-3-nitrobenzaldehyde 
• 51818-99-6 4-amino-3-nitro-benzaldehyde 
• 20274-69-5 (4-fluoro-3-nitrophenyl)methanol 
• 368427-56-9 5,11,17,23-tetra-tert-butyl-25-(4-formyl-2-nitrophenoxy)calix[4]arene-26,27,28-triol 
• 391213-68-6 (Z)-methyl 2-(acetylamino)-3-(4-fluoro-3-nitrophenyl)propenoate 
• 92498-33-4 4-(4-formyl-2-methoxyphenoxy)-3-nitrobenzaldehyde 
• 501931-57-3 2-nitro-biphenyl-4-carbaldehyde 
• 15017-52-4 4-(bromomethyl)-1-fluoro-2-nitrobenzene 
• 657409-24-0 tert-butyl (3-amino-4-fluorobenzyl)carbamate 
• 657409-25-1 C₁₄H₂₁FN₂O₆S₂ 
• 401907-70-8 C₂₁H₂₈FN₃O₄S₃ 
• 169825-21-2 D-(4-fluoro-3-nitrophenyl)glycine methyl ester 
• 331731-26-1 (R)-N-(tert-butoxycarbonyl)-4-fluoro-3-nitrophenylalanine methyl ester 
• 391213-74-4 (R)-2-[(R)-2-tert-Butoxycarbonylamino-2-(3-hydroxy-4-methoxy-phenyl)-acetylamino]-3-(4-fluoro-3-nitro-phenyl)-propionic acid methyl ester 

Relevant articles and documents

Design, synthesis and biological evaluation of phenyl urea derivatives as IDO1 inhibitors

Indoleamine 2,3-dioxygenase 1 (IDO1) is a heme-containing intracellular enzyme that catalyzes the first and rate-determining step of tryptophan metabolism and is an important immunotherapeutic target for the treatment of cancer. In this study, we designed and synthesized a new series of compounds as potential IDO1 inhibitors. These compounds were then evaluated for inhibitory activity against IDO1 and tryptophan 2,3-dioxygenase (TDO). Among them, the three phenyl urea derivatives i12, i23, i24 as showed potent IDO1 inhibition, with IC50 values of 0.1–0.6 μM and no compound exhibited TDO inhibitory activity. Using molecular docking, we predicted the binding mode of compound i12 within IDO1. Compound i12 was further investigated by determining its in vivo pharmacokinetic profile and anti-tumor efficacy. The pharmacokinetic study revealed that compound i12 had satisfactory properties in mice, with moderate plasma clearance (22.45 mL/min/kg), acceptable half-life (11.2 h) and high oral bioavailability (87.4%). Compound i12 orally administered at 15 mg/kg daily showed tumor growth inhibition (TGI) of 40.5% in a B16F10 subcutaneous xenograft model and 30 mg/kg daily showed TGI of 34.3% in a PAN02 subcutaneous xenograft model. In addition, the body weight of i12-treated mice showed no obvious reduction compared with the control group. Overall, compound i12 is a potent lead compound for developing IDO1 inhibitors and anti-tumor agents.

Piperidine compound and preparation method and medical application thereof

The invention discloses a piperidine compound shown as a formula (I) and a preparation method and medical application thereof, and particularly relates to a piperidine USP7 inhibitor compound or pharmaceutically acceptable salt or ester or solvate thereof and a preparation method and application of the piperidine USP7 inhibitor compound or pharmaceutically acceptable salt or ester or solvate thereof. The compound provided by the invention can inhibit the activity of USP7 enzyme, has very good selectivity and druggability, and can be used for preparing medicines for preventing or treating tumor diseases or virus infectious diseases.

COMPOUNDS WITH ANTIMICROBIAL ACTIVITY

Provided herein are compounds useful in the treatment of bacterial infections, pharmaceuticals comprising the same, and methods of use and preparation thereof.